Lipocine is trading 23.33% up at $2.59, with no clear catalyst identified. - The price has moved sharply from the October 6 close of $2.10. - Searches found no new company announcement on October 7 that clearly explains the move. - The latest notable company-specific news was the September 14 launch of a Phase 3 postpartum-depression study, which predates the rise. Broader markets and biotech sentiment were lower and do not explain it.